Nurix therapeutics announces extension of strategic collaboration with gilead sciences

Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the united states san francisco, april 02, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that gilead sciences has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years. “gilead's extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
NRIX Ratings Summary
NRIX Quant Ranking